Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Scherl

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Neuromuscular Disease|April 28, 2012
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel diseaseTing-Chin David Shen, Benjamin Lebwohl, Himanshu Verma, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factorsManasi Agrawal, Shirley Cohen-Mekelburg, Maia Kayal, et al.
Gastroenterology|October 4, 2021
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic InflammationSvetlana F Lima, Lasha Gogokhia, Monica Viladomiu, et al.
Crohn'S & Colitis 360|December 16, 2024
Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab TherapyRochelle Wong, Paris Charilaou, Amy Hemperly, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Inflammatory Bowel Diseases|July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 StudyScott D Lee, David T Rubin, William J Sandborn, et al.
Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.
Inflammatory Bowel Diseases|April 27, 2017
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative ColitisVinita Jacob, Carl Crawford, Shirley Cohen-Mekelburg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsJordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Cell Host & Microbe|February 15, 2019
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and ColitisLasha Gogokhia, Kate Buhrke, Rickesha Bell, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Neuromuscular Disease|April 28, 2012
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel diseaseTing-Chin David Shen, Benjamin Lebwohl, Himanshu Verma, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factorsManasi Agrawal, Shirley Cohen-Mekelburg, Maia Kayal, et al.
Gastroenterology|October 4, 2021
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic InflammationSvetlana F Lima, Lasha Gogokhia, Monica Viladomiu, et al.
Crohn'S & Colitis 360|December 16, 2024
Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab TherapyRochelle Wong, Paris Charilaou, Amy Hemperly, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Inflammatory Bowel Diseases|July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 StudyScott D Lee, David T Rubin, William J Sandborn, et al.
Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.
Inflammatory Bowel Diseases|April 27, 2017
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative ColitisVinita Jacob, Carl Crawford, Shirley Cohen-Mekelburg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsJordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Cell Host & Microbe|February 15, 2019
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and ColitisLasha Gogokhia, Kate Buhrke, Rickesha Bell, et al.
Pageof 6